2012
Serum levels of soluble CD25 as a marker for hepatocellular carcinoma
CABRERA R, FITIAN A, ARARAT M, XU Y, BRUSKO T, WASSERFALL C, ATKINSON M, LIU C, NELSON D. Serum levels of soluble CD25 as a marker for hepatocellular carcinoma. Oncology Letters 2012, 4: 840-846. PMID: 23205111, PMCID: PMC3506698, DOI: 10.3892/ol.2012.826.Peer-Reviewed Original ResearchSerum levelsEarly hepatocellular carcinomaHepatocellular carcinomaHCC presenceSoluble CD25Pg/Levels of sCD25Healthy control subjectsNovel predictive markerAdvanced cirrhosisPresent study studyAdvanced fibrosisTumor burdenTumor stageControl subjectsHCC patientsPredictive markerImmune factorsGlobal unmet needLarge cohortSCD25PatientsSmall seriesUnmet needSignificant positive correlation
2003
Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect
Nelson D, Tu Z, Soldevila‐Pico C, Abdelmalek M, Zhu H, Xu Y, Cabrera R, Liu C, Davis G. Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect. Hepatology 2003, 38: 859-868. PMID: 14512873, DOI: 10.1002/hep.1840380412.Peer-Reviewed Original ResearchConceptsIL-10HCV RNASerum ALTCytokine productionChronic hepatitis C patientsFunctional T cell analysesSerum HCV RNA levelsHCV-specific CD4Hepatic inflammation scoresIL-10 administrationInterleukin-10 therapyPBMC cytokine productionTh2 dominant profileHCV RNA levelsHepatitis C patientsT cell analysisTh2 cytokine productionAnti-inflammatory effectsAcute flaresC patientsDisease activityMeq/mLViral burdenAdvanced fibrosisLiver biopsy